You can save well for retirement, manage your IRA or 401(k) carefully, and even adjust spending downward when markets don’t cooperate. But there’s still a lurking threat to your retirement security you should know about…
After decades of building savings in a traditional individual retirement account, retirement may finally be within reach. But once retirees reach the required minimum distribution age, currently 73 for those born 1951–1959 and rising to…
GameStop shareholders approved a routine-sounding item on Tuesday: more authorized Class A shares. The timing complicates that read. Six days earlier, Sony confirmed it will stop manufacturing physical PlayStation game discs starting in January 2028,…
Broadcom (AVGO) got some cold water poured on it on July 7. Just one day after, the stock jumped on news that Apple (AAPL) had extended its chip supply agreement through 2031 in a deal…
If you have ever caught yourself doom scrolling on Instagram or Facebook for hours on end and felt bad, don’t; the technology is working exactly how it was intended to. Everything from the length and…
The Iran War, tariffs and the demand-driven AI-investment boon could add up to create inflationary conditions where Federal Reserve policymakers would need to consider interest-rate hikes later this year. But not just yet. According to…
T-Mobile is facing backlash for revoking a privilege that customers used when chatting with customer support representatives in the T-Life app. The change comes as the carrier has been making customers increasingly reliant on the…
International Business Machines (IBM) has spent years trying to convince investors that it deserves a new label. For Wall Street, IBM long looked like a legacy hardware and consulting company with limited upside. As IBM…
Tesla’s (TSLA) fresh bull case lands at a strange moment for the stock. Investors were anxiously waiting for a demand reset after concerns of some major EV competition, sluggish margins, and lackluster growth. However, in…
Eli Lilly (LLY) keeps setting records, and Wall Street’s rating of its stock keeps increasing as well. On Tuesday, one of JPMorgan’s most closely watched healthcare stock analysts, Chris Schott, who frequently covers Pfizer Inc.…